Impact of weight loss on ablation outcome in obese patients with longstanding persistent atrial fibrillation

J Cardiovasc Electrophysiol. 2018 Feb;29(2):246-253. doi: 10.1111/jce.13394. Epub 2017 Dec 26.

Abstract

Aims: This study investigated the impact of weight loss in longstanding persistent (LSPAF) patients undergoing catheter ablation (CA).

Methods: Ninety consecutive obese LSPAF patients were approached; 58 volunteered to try weight loss interventions for up to 1 year (group 1), while 32 patients declined weight loss interventions and were included as a control (group 2). Both groups remained on antiarrhythmic drugs. If they continued to experience AF, CA was performed. Body weight was measured at 6-month intervals and arrhythmia status was assessed by event recorder, electrocardiogram (ECG), and Holter monitoring. Symptom severity and quality of life (QoL) were evaluated by AFSS and SF-36 survey, respectively. A scoring algorithm with two summary measures, physical component score (PCS) and mental component score (MCS), was prepared for QoL analysis.

Results: Significant reduction in body weight (median -24.9 (IQR -19.1 to -56.7) kg, P < 0.001) was observed in the group 1 patients, while no such change was seen in group 2. The PCS and MCS scores improved significantly in group 1 only, with a change from baseline of 8.4 ± 3 (P = 0.013) and 12.8 ± 8.2 (P < 0.02). However, AF symptom severity remained unchanged from baseline in both groups (P = 0.84). All 90 patients eventually underwent CA and received PVAI+ posterior wall+ non-PV triggers ablation. At 1-year follow-up after single procedure, 37 (63.8%) in group 1 and 19 (59.3%) patients in group 2 remained arrhythmia-free off AAD (P = 0.68).

Conclusion: In this prospective analysis, in LSPAF patients weight loss improved QoL but had no impact on symptom severity and long-term ablation outcome.

Keywords: AF recurrence; catheter ablation; longstanding persistent AF; quality of life; symptom severity; weight loss.

Publication types

  • Observational Study

MeSH terms

  • Action Potentials
  • Aged
  • Anti-Arrhythmia Agents / therapeutic use
  • Atrial Fibrillation / complications
  • Atrial Fibrillation / diagnosis
  • Atrial Fibrillation / physiopathology
  • Atrial Fibrillation / surgery*
  • Case-Control Studies
  • Catheter Ablation* / adverse effects
  • Databases, Factual
  • Electrocardiography, Ambulatory
  • Female
  • Heart Rate
  • Humans
  • Male
  • Middle Aged
  • Obesity / complications
  • Obesity / diagnosis
  • Obesity / physiopathology
  • Obesity / therapy*
  • Progression-Free Survival
  • Prospective Studies
  • Quality of Life
  • Recurrence
  • Severity of Illness Index
  • Time Factors
  • Weight Loss*

Substances

  • Anti-Arrhythmia Agents